摘要
目的:对比傲迪适(DEX)与阿柏西普注射治疗糖尿病性黄斑水肿的疗效。方法:选取2019—2021年于我院接受治疗的80例糖尿病性黄斑水肿患者作为研究对象,根据治疗方案不同将患者分为观察组(n=40)和对照组(n=40)。对照组采用阿柏西普注射治疗,观察组采用DEX治疗,比较两组临床疗效、最佳矫正视力(BCVA)、黄斑部中心凹视网膜厚度(CFT)、眼压情况、生活质量以及不良反应发生情况。结果:观察组临床总有效率为95.00%,高于对照组的92.50%,但差异无统计学意义(P>0.05);两组术前及术后1个月、3个月、6个月BCVA、CFT、眼压比较,差异无统计学意义(P>0.05);两组术后6个月生活质量评分高于术前(P<0.05),但组间比较,差异无统计学意义(P>0.05);观察组不良反应发生率为2.50%,低于对照组的15.00%,差异有统计学意义(P<0.05)。结论:DEX与阿柏西普注射治疗糖尿病性黄斑水肿的临床疗效相当,均可改善患者视力水平、黄斑部中心凹视网膜厚度、眼压情况及生活质量,但DEX治疗方法产生的不良反应更少,安全性更高。
Objective:To compare the curative effect of aladiazepine(DEX) and abcept injection in the treatment of diabetic macular edema.Methods:A total of 80 patients with diabetic macular edema who were treated in our hospital from 2019 to 2021 were selected as the research subjects.According to different treatment regimens,the patients were divided into observation group(n=40) and control group(n=40).The control group was treated with Abercept injection,and the observation group was treated with DEX.The clinical efficacy,best corrected visual acuity(BCVA),central foveal retinal thickness(CFT),intraocular pressure,quality of life and adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 95.00%,which was higher than 92.50% of the control group,but the difference was not statistically significant(P>0.05).There was no significant difference in BCVA,CFT and intraocular pressure between the two groups before operation and 1 month,3 months and 6 months after operation(P>0.05).The quality of life scores at 6 months after operation in the two groups were higher than those before operation(P<0.05),however,the difference between groups was not statistically significant(P>0.05).The incidence of adverse reactions in the observation group was 2.50%,which was lower than 15.00% in the control group,and the difference was statistically significant(P<0.05).Conclusion:The clinical efficacy of DEX and Abercept injection in the treatment of diabetic macular edema is equivalent,which can improve the visual acuity,macular central concave retinal thickness,intraocular pressure and quality of life of patients.However,DEX treatment has fewer adverse reactions and higher safety.
作者
陈焓
庄静宜
周真宝
胡艳霞
杨玲玲
石亚琳
CHEN Han;ZHUANG Jingyi;ZHOU Zhenbao;HU Yanxia;YANG Lingling;SHI Yalin(Department of Ophthalmology,The First Affiliated Hospital of Xiamen University,Xiamen 361003,Fujian,China)
出处
《中国药物滥用防治杂志》
CAS
2022年第11期1637-1641,1645,共6页
Chinese Journal of Drug Abuse Prevention and Treatment